<?xml version='1.0' encoding='utf-8'?>
<document id="24619917"><sentence text="Pharmacokinetic and pharmacodynamic drug-drug interaction assessment between pradigastat and digoxin or warfarin."><entity charOffset="93-100" id="DDI-PubMed.24619917.s1.e0" text="digoxin" /><entity charOffset="104-112" id="DDI-PubMed.24619917.s1.e1" text="warfarin" /><pair ddi="false" e1="DDI-PubMed.24619917.s1.e0" e2="DDI-PubMed.24619917.s1.e0" /><pair ddi="false" e1="DDI-PubMed.24619917.s1.e0" e2="DDI-PubMed.24619917.s1.e1" /></sentence><sentence text="Pradigastat, a novel diacylglycerol acyltransferase-1 inhibitor, was evaluated for both pharmacokinetic (PK) and pharmacodynamic (PD) drug-drug interactions when co-administered with digoxin or warfarin in healthy subjects"><entity charOffset="21-35" id="DDI-PubMed.24619917.s2.e0" text="diacylglycerol" /><entity charOffset="183-190" id="DDI-PubMed.24619917.s2.e1" text="digoxin" /><entity charOffset="194-202" id="DDI-PubMed.24619917.s2.e2" text="warfarin" /><pair ddi="false" e1="DDI-PubMed.24619917.s2.e0" e2="DDI-PubMed.24619917.s2.e0" /><pair ddi="false" e1="DDI-PubMed.24619917.s2.e0" e2="DDI-PubMed.24619917.s2.e1" /><pair ddi="false" e1="DDI-PubMed.24619917.s2.e0" e2="DDI-PubMed.24619917.s2.e2" /><pair ddi="false" e1="DDI-PubMed.24619917.s2.e1" e2="DDI-PubMed.24619917.s2.e1" /><pair ddi="false" e1="DDI-PubMed.24619917.s2.e1" e2="DDI-PubMed.24619917.s2.e2" /></sentence><sentence text=" This open-label study included two parallel subject cohorts each with three sequential treatment periods" /><sentence text=" Forty subjects were enrolled in the study with 20 subjects allocated to each cohort" /><sentence text=" PK and PD (PT/INR for warfarin only) samples were collected in each period" /><sentence text=" The statistical analysis results showed that the 90% CIs of the geometric mean ratios of digoxin, R-warfarin, and S-warfarin PK parameters (AUC and Cmax) were all within 0"><entity charOffset="90-97" id="DDI-PubMed.24619917.s6.e0" text="digoxin" /><entity charOffset="99-109" id="DDI-PubMed.24619917.s6.e1" text="R-warfarin" /><pair ddi="false" e1="DDI-PubMed.24619917.s6.e0" e2="DDI-PubMed.24619917.s6.e0" /><pair ddi="false" e1="DDI-PubMed.24619917.s6.e0" e2="DDI-PubMed.24619917.s6.e1" /></sentence><sentence text="80-1" /><sentence text="25 interval" /><sentence text=" The 90% CIs of the geometric mean ratios of pradigastat PK parameters (AUC and Cmax) were within 0" /><sentence text="80-1" /><sentence text="25 interval when co-administered with warfarin; while co-administration with digoxin slightly reduced pradigastat exposure (âˆ¼15%)"><entity charOffset="38-46" id="DDI-PubMed.24619917.s11.e0" text="warfarin" /><entity charOffset="77-84" id="DDI-PubMed.24619917.s11.e1" text="digoxin" /><pair ddi="false" e1="DDI-PubMed.24619917.s11.e0" e2="DDI-PubMed.24619917.s11.e0" /><pair ddi="false" e1="DDI-PubMed.24619917.s11.e0" e2="DDI-PubMed.24619917.s11.e1" /></sentence><sentence text=" The results also showed that 90% CIs of the geometric mean ratios of warfarin PD parameters (AUC(PT), PTmax, AUC(INR), and INRmax) were within 0" /><sentence text="80-1" /><sentence text="25 interval" /><sentence text=" Pradigastat and digoxin or warfarin had no relevant clinical PK or PD drug-drug interactions"><entity charOffset="17-24" id="DDI-PubMed.24619917.s15.e0" text="digoxin" /><entity charOffset="28-36" id="DDI-PubMed.24619917.s15.e1" text="warfarin" /><pair ddi="false" e1="DDI-PubMed.24619917.s15.e0" e2="DDI-PubMed.24619917.s15.e0" /><pair ddi="false" e1="DDI-PubMed.24619917.s15.e0" e2="DDI-PubMed.24619917.s15.e1" /></sentence><sentence text=" Administration of pradigastat and warfarin or pradigastat and digoxin as a mono or combined treatment appears to be safe and tolerated"><entity charOffset="63-70" id="DDI-PubMed.24619917.s16.e0" text="digoxin" /></sentence><sentence text="" /></document>